Integrated Diagnostics Holdings Stock Net Income
| IDHC Stock | 0.40 0.02 5.26% |
Integrated Diagnostics Holdings fundamentals help investors to digest information that contributes to Integrated Diagnostics' financial success or failures. It also enables traders to predict the movement of Integrated Stock. The fundamental analysis module provides a way to measure Integrated Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Diagnostics stock.
| Last Reported | Projected for Next Year | ||
| Net Income | 737.4 M | 723.7 M | |
| Net Income From Continuing Ops | 468.4 M | 511.4 M | |
| Net Income Applicable To Common Shares | 1.6 B | 1.7 B |
Integrated | Net Income |
Integrated Diagnostics Holdings Company Net Income Analysis
Integrated Diagnostics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Integrated Diagnostics Net Income | 737.36 M |
Most of Integrated Diagnostics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Diagnostics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Integrated Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Integrated Diagnostics Holdings reported net income of 737.36 M. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The net income for all United Kingdom stocks is notably lower than that of the firm.
Integrated Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Diagnostics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integrated Diagnostics could also be used in its relative valuation, which is a method of valuing Integrated Diagnostics by comparing valuation metrics of similar companies.Integrated Diagnostics is currently under evaluation in net income category among its peers.
Integrated Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0969 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 232.12 M | ||||
| Shares Outstanding | 581.33 M | ||||
| Shares Owned By Insiders | 33.97 % | ||||
| Shares Owned By Institutions | 42.29 % | ||||
| Price To Book | 4.15 X | ||||
| Price To Sales | 0.05 X | ||||
| Revenue | 4.12 B | ||||
| Gross Profit | 2.8 B | ||||
| EBITDA | 1.28 B | ||||
| Net Income | 737.36 M | ||||
| Total Debt | 1.18 B | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | 543.66 M | ||||
| Earnings Per Share | 0.03 X | ||||
| Target Price | 27.67 | ||||
| Number Of Employees | 6.69 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 23.25 B | ||||
| Total Asset | 5.77 B | ||||
| Retained Earnings | 1.33 B | ||||
| Working Capital | 686.94 M | ||||
| Net Asset | 5.77 B |
About Integrated Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integrated Diagnostics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Diagnostics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Integrated Stock Analysis
When running Integrated Diagnostics' price analysis, check to measure Integrated Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Diagnostics is operating at the current time. Most of Integrated Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integrated Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Diagnostics' price. Additionally, you may evaluate how the addition of Integrated Diagnostics to your portfolios can decrease your overall portfolio volatility.